7618 Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
given concurrently with chemotherapy do not improve patient (pt) outcomes compared with …

Background Earlier preclinical and phase II research showed enhanced effect of docetaxel
plus intercalated erlotinib. The NVALT-18 phase III study was designed to compare …

7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly
prolonged survival, delayed symptom progression, and improved quality of life versus …

Background: Erlotinib is proven to prolong survival, delay symptom progression and improve
quality of life for pts with advanced NSCLC (Shepherd et al. N Engl J Med 2005; 353: 123 …

Background Erlotinib, docetaxel, and pemetrexed are approved for the second-line
treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large …

Purpose A prior study demonstrated that addition of continuous daily erlotinib fails to
improve response rate or survival in non–small-cell lung cancer (NSCLC) patients treated …

Background In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …

Introduction Little data is available on patients with advanced non-squamous NSCLC
treated with erlotinib specifically after failure of first-line pemetrexed-containing …

Purpose: The purpose of the present trial was to investigate whether clinical benefit can be
obtained by concurrent administration of erlotinib with gemcitabine as first-line treatment in …

BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …